Angiolymphatic invasion exerts a strong impact on surgical outcomes for stage I lung adenocarcinoma, but not non-adenocarcinoma

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 394-400

  Kato, Tatsuya ^a,b   Ishikawa, Keidai ^a   Aragaki, Masato ^a   Sato, Masaaki ^c   Okamoto, Kenzo ^d   Ishibashi, Tetsuya ^a   Kaji, Mitsuhito ^a  

^a Sapporo Minami Sanjo Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Sapporo Medical Center   (Japan)

^d Japan Labor Health and Welfare Organization   (Japan)

Author keywords

Angiolymphatic invasion; Lung cancer; Prognostic factor; Vessel invasion

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ANGIOLYMPHATIC INVASION; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LARGE CELL CARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PLEURAL INVASION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84863784159     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.04.002     Document Type: Article

References (21)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36.
2. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717.
3. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.
4. Sobin L., Gospodarowicz M., Wittekind C. International union against cancer (UICC) TNM classification of malignant tumours 2009, Wiley-Blackwell, Oxford, UK. 7th ed.
5. Goldstein N.S., Mani A., Chmielewski G., Welsh R., Pursel S. Prognostic factors in T1 NO MO adenocarcinomas and bronchioloalveolar carcinomas of the lung. Am J Clin Pathol 1999, 112:391-402.
6. Pechet T.T., Carr S.R., Collins J.E., Cohn H.E., Farber J.L. Arterial invasion predicts early mortality in stage I non-small cell lung cancer. Ann Thorac Surg 2004, 78:1748-1753.
7. Tsuchiya T., Akamine S., Muraoka M., Kamohara R., Tsuji K., Urabe S., et al. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 2007, 56:341-348.
8. Schuchert M.J., Schumacher L., Kilic A., Close J., Landreneau J.R., Pennathur A., et al. Impact of angiolymphatic and pleural invasion on surgical outcomes for stage I non-small cell lung cancer. Ann Thorac Surg 2011, 91:1059-1065. discussion 65.
9. Funai K., Sugimura H., Morita T., Shundo Y., Shimizu K., Shiiya N. Lymphatic vessel invasion is a significant prognostic indicator in stage IA lung adenocarcinoma. Ann Surg Oncol 2011, 18:2968-2972.
10. Faoro L., Hutto J.Y., Salgia R., El-Zayaty S.A., Ferguson M.K., Cheney R.T., et al. Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. Arch Pathol Lab Med 2008, 132:1882-1888.
11. Iwakiri S., Nagai S., Katakura H., Takenaka K., Date H., Wada H., et al. D2-40-positive lymphatic vessel density is a poor prognostic factor in squamous cell carcinoma of the lung. Ann Surg Oncol 2009, 16:1678-1685.
12. Travis W., Brambilla E., Muller-Hermelink H., Harris C. International histological classification of tumours 2004, IARC Press, Lyon. 3rd ed.
13. Kessler R., Gasser B., Massard G., Roeslin N., Meyer P., Wihlm J.M., et al. Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer. Ann Thorac Surg 1996, 62:1489-1493.
14. Bodendorf M.O., Haas V., Laberke H.G., Blumenstock G., Wex P., Graeter T. Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma. Lung Cancer 2009, 64:71-78.
15. Kato H., Ichinose Y., Ohta M., Hata E., Tsubota N., Tada H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004, 350:1713-1721.
16. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
17. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005, 352:2589-2597.
18. Kahn H.J., Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002, 82:1255-1257.
19. Yoon S.O., Kim Y.T., Jung K.C., Jeon Y.K., Kim B.H., Kim C.W. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung Cancer 2011, 71:209-216.
20. Krebs M.G., Sloane R., Priest L., Lancashire L., Hou J.M., Greystoke A., et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011, 29:1556-1563.
21. Hofman V., Bonnetaud C., Ilie M.I., Vielh P., Vignaud J.M., Flejou J.F., et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 2011, 17:827-835.